Back to Browse Journals » Biologics: Targets and Therapy » Volume 3

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs

Authors Manil Kukar, Olga Petryna, Petros Efthimiou

Published Date September 2009 Volume 2009:3 Pages 443—457


Published 28 September 2009

Manil Kukar1, Olga Petryna1, Petros Efthimiou2

1Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USA

Abstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the role of cytokines has enabled the development of innovative biological agents in the last 10 years that target specific parts of the immune response. Failure to achieve adequate response with traditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing radiographic deterioration of the affected joints despite seemingly clinical response were essential stimuli for the development of biologics. The current and upcoming biological agents are primarily aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to inflammation. These agents have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. However, use of these agents has also been associated with significant, although rare, adverse events and considerable cost. Therefore, these agents should be used with caution by experienced clinicians. The present work aims to provide a global and updated review of the current and in-development biological DMARDs for the treatment of RA.

Keywords: biological agents, rheumatoid arthritis, immunomodulators, treatment, cytokines

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Assessment of clinical effects and safety of an oral supplement based on marine protein, vitamin C, grape seed extract, zinc, and tomato extract in the improvement of visible signs of skin aging in men

Costa A, Pegas Pereira ES, Assumpção EC, Calixto dos Santos FB, Ota FS, de Oliveira Pereira M, Fidelis MC, Fávaro R, Barros Langen SS, Favaro de Arruda LH, Abildgaard EN

Clinical, Cosmetic and Investigational Dermatology 2015, 8:319-328

Published Date: 29 June 2015

Single event-related changes in cerebral oxygenated hemoglobin using word game in schizophrenia

Fujiki R, Morita K, Sato M, Yamashita Y, Kato Y, Ishii Y, Shoji Y, Uchimura N

Neuropsychiatric Disease and Treatment 2014, 10:2353-2360

Published Date: 11 December 2014

An update on belimumab for the treatment of lupus

Aikaterini Thanou-Stavraki, Amr H Sawalha,

Biologics: Targets and Therapy 2011, 5:33-43

Published Date: 14 February 2011

New and emerging treatment approaches to lupus

Marion Haubitz

Biologics: Targets and Therapy 2010, 4:263-271

Published Date: 6 September 2010

Safety of etanercept in elderly subjects with rheumatoid arthritis

Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, et al

Biologics: Targets and Therapy 2010, 4:1-4

Published Date: 22 December 2009

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

Junichiro Sageshima, Gaetano Ciancio, Linda Chen, George W Burke III

Biologics: Targets and Therapy 2009, 3:319-336

Published Date: 17 June 2009

Front line treatment of elderly multiple myeloma in the era of novel agents

Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al

Biologics: Targets and Therapy 2009, 3:99-109

Published Date: 30 October 2008